S-1 Plus Sorafenib May Be Safe, Effective for Renal Cell Carcinoma

Share this content:
Combination therapy with S-1 plus sorafenib is effective and tolerable as treatment for patients with metastatic renal cell carcinoma.
Combination therapy with S-1 plus sorafenib is effective and tolerable as treatment for patients with metastatic renal cell carcinoma.

Combination therapy with S-1 plus sorafenib is effective and tolerable as treatment for patients with metastatic renal cell carcinoma, a new study published online ahead of print in the journal Annals of Oncology has shown.

For the single-arm, open-label, phase 1/2 study, researchers sought to evaluate the clinical activity, safety, tolerance, and pharmacokinetics of S-1 plus sorafenib in patients with metastatic renal cell carcinoma.

Researchers enrolled nine patients into phase 1 and 21 patients into phase 2. Of those 21, six had received the recommended dose in phase 1. All participants were diagnosed with clear-cell or papillary renal cell carcinoma who had received no more than one prior cytokine-based regimen.

The recommended dose of therapy was S-1 80 mg/m2/day on days 1 to 28 with sorafenib 800 mg/day on days 1 to 42.

Results showed that among the 21 evaluable patients in phase 2, the confirmed overall response rate was 52% (95% CI: 29.8, 74.3). One patient achieved a complete response and 10 patients achieved partial responses.

Researchers found that median progression-free survival was 9.9 months (95% CI: 6.5, 17.1).

RELATED: Functional Adaptive Hyperfiltration May Affect Renal Function after Radical Nephrectomy

In regard to safety, all patients experienced treatment-related hand-foot skin reactions, which resulted in dose reductions in 38% of patients.

The findings suggest that although S-1 and sorafenib combination therapy appears to be effective and tolerable for patients with metastatic renal cell carcinoma, skin event management is necessary for patients receiving this therapy.

Reference

  1. Naito S, Sakai H, Hashine K, et al. Phase 1/2 study of S-1 in combination with sorafenib for metastatic renal cell carcinoma.Ann Oncol. 2015. [epub ahead of print]. doi: 10.1093/annonc/mdv280.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters